Author(s):
Patil Hetakshi Vilas, Patil Harshada Kailas, Patel Sejal Tukaram, Pawar Mohit Sunil, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar
Email(s):
patilhetakshi18@gmail.com , patilharshada1782001@gmail.com , sejalpatel1322001@gmail.com , mohitpawar477@gmail.com , laxmipremchandani3@gmail.com , dhankaniamit@gmail.com , sppawar75@rediffmail.com
DOI:
10.52711/2231-5675.2025.00037 
Address:
Patil Hetakshi Vilas, Patil Harshada Kailas, Patel Sejal Tukaram, Pawar Mohit Sunil, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar
P.S.G.V.P Mandal’s College of Pharmacy Shahada, Dist- Nandurbar--425409, Maharashtra-India
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2024
ABSTRACT:
Ertugliflozin, being an SGLT2 inhibitor, is extensively applied in managing type 2 diabetes mellitus through enhancing glycemic control. With the pharmaceutical industries seeking compliance with regulatory requirements, the demand for accurate, dependable, and effective analytical methods for the determination and quality assessment of ertugliflozin has grown. In this article, the authors give an extensive overview of different analytical methodologies designed for determining ertugliflozin in pharmaceutical formulation, bulk samples, and in biological matrices. The major thrust is given to chromatographic methodology, especially to high-performance liquid chromatography (HPLC), which has been the best choice owing to its ruggedness, accuracy, and precision. We assess various detection methods used in conjunction with HPLC, such as UV and fluorescence, and development of reversed-phase HPLC (RP-HPLC) for enhanced resolution. We also discuss alternative methodologies like spectrophotometric and electrochemical methodologies, each possessing unique advantages for matrix and analysis needs. Important factors that go into method development, such as column type, detection wavelength, and mobile phase composition, are elaborated at length. In addition, critical validation parameters like linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ) are tested in accordance with the International Council for Harmonization (ICH) and other regulatory agency guidelines.
Cite this article:
Patil Hetakshi Vilas, Patil Harshada Kailas, Patel Sejal Tukaram, Pawar Mohit Sunil, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar. Ertugliflozin Analysis: Chromatographic and Spectrophotometric Approaches. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):236-2. doi: 10.52711/2231-5675.2025.00037
Cite(Electronic):
Patil Hetakshi Vilas, Patil Harshada Kailas, Patel Sejal Tukaram, Pawar Mohit Sunil, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar. Ertugliflozin Analysis: Chromatographic and Spectrophotometric Approaches. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):236-2. doi: 10.52711/2231-5675.2025.00037 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-15-3-13
REFERENCES:
1. Markham A. Ertugliflozin: first global approval. Drugs. 2018; 78(4): 513-9. doi: 10.1007/s40265-018-0874-8.
2. Haider K, Pathak A, Rohilla A, Haider MR, Ahmad K, Yar MS. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. European Journal of Medicinal Chemistry. 2019; 184: 111773. doi: 10.1016/j.ejmech.2019.111773.
3. Cinti F, Moffa S, Impronta F, Cefalo CMA, Sun VA, Sorice G, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date. Drug Design, Development and Therapy. 2017; 11:2905-19. doi: 10.2147/DDDT.S141849.
4. Merck and Co Inc. STEGLATRO™ (ertugliflozin) tablets, for oral use: prescribing information. 2017. Available from: http://www.merck.com/. Accessed 9 Feb 2018.
5. Merck and Co Inc. SEGLUROMET™ (ertugliflozin and metformin hydrochloride) tablets, for oral use: prescribing information. 2017. Available from: http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
6. Merck and Co Inc. STEGLUJAN™ (ertugliflozin and sitagliptin) tablets, for oral use: prescribing information. 2017. Available from: http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
7. European Medicines Agency. CHMP summary of opinion Seglurome(ertugliflozin/metformin). 2018. http://www.ema. europa.eu/. Accessed 9 Feb 2018
8. European Medicines Agency. CHMP summary of opinion: Steglujan (ertugliflozin/sitagliptin). 2018.
9. Merck and Co Inc. Steglatro (ertugliflozin) [package insert]. Whitehouse Station, NJ: Merck and Co Inc.; 2020. Available from: https://www.merckconnect.com/steglatro/patient-education/.
10. Dawra VK, Liang Y, Shi H, et al. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 2019; 57(4): 207-16. doi: 10.5414/CP203343.
11. Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes, Obesity and Metabolism. 2019; 21(Suppl 2): 34-42. doi: 10.1111/dom.13611.
12. Sasidharan S, Saad S, Hui WY. Ultra Performance Liquid Chromatography (UPLC): A preeminent technique in pharmaceutical analysis. ResearchGate. 2015. Available from: https://www.researchgate.net/publication/288227077_
13. Bhavya K, Vishnumurthy KM, Rambabu D, Sumakanth M. ICH guidelines – “Q” series (quality guidelines) - A review. GSC Biological and Pharmaceutical Sciences. 2019; 6(3): 89-106.
14. Skoog DA, Holler FJ, Crouch SR. Principles of Instrumental Analysis. 6th ed. Belmont, CA: Thomson Brooks/Cole; 2007. p. 169-173. ISBN: 978-0-495-01201-6.
15. Synovec RE, et al. new directions in process gas chromatography. IFPAC-98 Presentation. 1968;1-66.
16. Sheliya KG, Shah KV. Ultra Performance Liquid Chromatography (UPLC): A modern chromatography technique. Pharma Science Monitor: An International Journal of Pharmaceutical Sciences. Vol. 4.
17. Wu N, Lippert JA, Lee ML. Practical aspects of ultrahigh pressure capillary liquid chromatography. Journal of Chromatography. 2001; 1:9-11.
18. McNair HM, Miller JM. Basic Gas Chromatography. John Wiley and Sons, Inc.; 1998. p. 29-52.
19. Halasz I, Gerlach HO. Micropacked columns. Analytical Chemistry. 1966; 38: 281.
20. Guillemin CL, et al. Rapid gas chromatographic analysis on Spherosil. Journal of Chromatography. 1973; 84: 21-36.
21. Frank D, Sandra P. Use of hydrogen as carrier gas in capillary GC. American Laboratory. 1999; 18.
22. Alltech Bulletin. Bringing speed to gas chromatography. Bulletin. 1995; 328: 56-71.
23. Martin AJ. Linear programmed temperature gas chromatography to 500°C. Edinburgh Symposium. London: Butterworths; 1960. p. 208-10.
24. Emery EM, Koerner WE. Dual column programmed temperature gas chromatography. Analytical Chemistry. 1962; 34:1196-8.
25. Waditake PD, Kolhe MH, Mate MK, Bhor RJ, Bhalerao PS, Mhaske MP. Stability Indicating Bioanalytical Method Development and Validation for Estimation of Remogliflozin Etabonate by RP-HPLC in Human Plasma. International Journal of Pharmaceutical Investigation. 2024; 14(4): 1131-7. doi: 10.5530/ijpi.14.4.123.
26. Bamniya J, Manocha N, Choudhary S, Dubey PK. Analytical Method Development by HPLC to Evaluate the Stress Degradation Stability Profile of Ertugliflozin. International Journal of Pharmaceutical Sciences and Medicine. 2023; 8(6): 139-153. doi: 10.47760/ijpsm. 2023.v08i06.009.
27. Mankar SD, Sagar P, Bhawar S, Siddheshwar S, Dighe S. Development and validation of RP-HPLC method for simultaneous estimation of Ertugliflozin and Sitagliptin in bulk drug and tablet dosage form. International Journal of Experimental Research and Review. 2023; 32: 288-96. doi: 10.52756/ijerr. 2023.v32.025.
28. Ghante MR, Tangade RB, Sawant SD, Kulkarni PD, Bhusari VK. Development and Validation of stability indicating RP-HPLC method for the estimation of Ertugliflozin by forced degradation studies. Research Journal of Pharmacy and Technology. 2022;15(11):4945-9. doi: 10.52711/0974-360X.2022.00831.
29. Shelke S, Singh N. Development and Validation of HPLC Method for Determination of Ertugliflozin Impurity Profile. Journal of Population Therapeutics and Clinical Pharmacology. 2022; 29(4): 4326-52. doi: 10.53555/fa0e7p09.
30. Srinivasan R, Ahamed CASF. Validation of Developed Analytical Methods for the Determination of Remogliflozin and Ertugliflozin in Pharmaceutical Dosage Forms - An Updated Review. International Journal of Pharmaceutical Sciences Review and Research. 2022; 72(1): 29-34. doi: 10.47583/ijpsrr.2022.v72i01.005.
31. Itigimatha N, Chadchan KS, Yallur BC, Hadagali MD. Simple and Sensitive RP-HPLC and UV Spectroscopic Methods for the Determination of Remogliflozin Etabonate in Pure and Pharmaceutical Formulations. Turkish Journal of Pharmaceutical Sciences. 2022; 19(2): 213-219. doi: 10.4274/tjps.galenos.2021.55381.
32. Kumari KS, Bandhakavi S. Development and validation of stability-indicating RP-HPLC method for the simultaneous determination of ertugliflozin pidolate and metformin hydrochloride in bulk and tablets. Future Journal of Pharmaceutical Sciences. 2020; 6: 66. doi: 10.1186/s43094-020-00079-1.
33. Suneetha A, Sharmila D. A validated stability-indicating RP-HPLC method for estimation of canagliflozin in dosage form. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2015; 6(5):1186-94.
34. Kagarana CS, Patel KN, Patel AB. Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Metformin Hydrochloride and Remogliflozin Etabonate in Bulk and Tablet Formulation. Research Journal of Pharmacy and Technology. 2024; 17(5): 2025-30. doi: 10.52711/0974-360X.2024.00320.
35. Kagarana CS, Patel KN, Patel AB. Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Metformin Hydrochloride and Remogliflozin Etabonate in Bulk and Tablet Formulation. Research Journal of Pharmacy and Technology. 2024; 17(5): 2025-30. doi: 10.52711/0974-360X.2024.00320